BCC 2021 | Highlights from the St. Gallen Consensus Panel
Giuseppe Curigliano, MD, PhD, University of Milan, Milan, Italy, discusses highlights from the virtual 17th St. Gallen International Breast Cancer Consensus session on the optimal treatment of women with early breast cancer, including conversations on the use of pathological complete response as a surrogate marker for long-term outcomes, the role of gene signatures in stratifying risk in the adjuvant setting as well as the use of carboplatin in the neoadjuvant setting. This interview took place during the 17th St. Gallen International Breast Cancer Conference.
Disclosures
Dr. Curigliano reports personal fees from Roche, Pfizer, Novartis, Lilly, Foundation Medicine, BMS, Samsung, Astra Zeneca, Daichii Sankyo, Boeringer, GSK, Seagen, Roche, Novartis, Pfizer, Lilly, Foundation Medicine, Samsung, Daichii Sankyo, non-financial support from Roche, Pfizer, grants from Merck, and other from Ellipsis
